{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T08:44:06Z","timestamp":1773305046746,"version":"3.50.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1186\/s12913-015-1134-3","type":"journal-article","created":{"date-parts":[[2015,10,26]],"date-time":"2015-10-26T17:08:02Z","timestamp":1445879282000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Costs and utilization of treatment in patients with hemophilia"],"prefix":"10.1186","volume":"15","author":[{"given":"Patr\u00edcia","family":"Rocha","sequence":"first","affiliation":[]},{"given":"Manuela","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Ara\u00fajo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2015,10,26]]},"reference":[{"key":"1134_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci PM, Tuddenham EG. The hemophilias - from royal genes to gene therapy. N Engl J Med. 2001;344:1773\u20139.","journal-title":"N Engl J Med."},{"key":"1134_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1538-7836.2008.03246.x","volume":"7","author":"C Costa","year":"2009","unstructured":"Costa C, Frances AM, Letourneau S, Girondon-Boulandet E, Goossens M. Mosaicism in men in hemophilia: is it exceptional? Impact on genetic counselling. J Thromb Haemost. 2009;7:367\u20139.","journal-title":"J Thromb Haemost."},{"key":"1134_CR3","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1046\/j.1365-2516.2003.00779.x","volume":"9","author":"S Paisley","year":"2003","unstructured":"Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice. Haemophilia. 2003;9:405\u201317.","journal-title":"Haemophilia."},{"key":"1134_CR4","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/hae.12291","volume":"20","author":"J Elander","year":"2014","unstructured":"Elander J. A review of evidence about behavioural and psychological aspects of chronic joint pain among people with haemophilia. Haemophilia. 2014;20:168\u201375.","journal-title":"Haemophilia."},{"key":"1134_CR5","first-page":"1","volume":"684","author":"SA Larsson","year":"1984","unstructured":"Larsson SA. Hemophilia in Sweden. Studies on demography of hemophilia and surgery in hemophilia and von Willebrand's disease. Acta Medica Scandinavica Suppl. 1984;684:1\u201332.","journal-title":"Acta Medica Scandinavica Suppl"},{"key":"1134_CR6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/asheducation-2013.1.30","volume":"2013","author":"RJ Kaufman","year":"2013","unstructured":"Kaufman RJ, Powell JS. Molecular approaches to improved clotting factors for hemophilia. Hematology Am Soc Hematol Educ Program. 2013;2013:30\u20136.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"Suppl 1","key":"1134_CR7","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2516.9.s1.14.x","volume":"9","author":"W Schramm","year":"2003","unstructured":"Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia. 2003;9 Suppl 1:111\u20136.","journal-title":"Haemophilia"},{"key":"1134_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/j.1365-2516.2006.01370.x","volume":"12","author":"M Ullman","year":"2006","unstructured":"Ullman M, Hoots WK. Assessing the costs for clinical care of patients with high responding factor VIII and IX inhibitors. Haemophilia. 2006;12:74\u201380.","journal-title":"Haemophilia."},{"issue":"Suppl 1","key":"1134_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/j.1355-0691.2004.00881.x","volume":"10","author":"D Globe","year":"2004","unstructured":"Globe D, Curtis R, Koerper M, HUGS Steering Committee. Utilization of care in haemophilia: a resource based method for cost analysis from the Haemophilia Utilization Group Study (HGS). Haemophilia. 2004;10 Suppl 1:63\u20137.","journal-title":"Haemophilia"},{"key":"1134_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1046\/j.1365-2516.2003.00764.x","volume":"9","author":"K Fischer","year":"2003","unstructured":"Fischer K, Van Den Berg M. Prophylaxis for severe hemophilia: clinical and economical issues. Haemophilia. 2003;9:376\u201381.","journal-title":"Haemophilia."},{"key":"1134_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","volume":"9","author":"J Wight","year":"2003","unstructured":"Wight J, Paisley S. The epidemiology of inhibitors in hemophilia A: a systematic review. Haemophilia. 2003;9:418\u201335.","journal-title":"Haemophilia."},{"key":"1134_CR12","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1365-2125.2010.03899.x","volume":"72","author":"M Franchini","year":"2011","unstructured":"Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VII, IX and XI): a review of current therapeutic pratice. J Clinical Pharmacol. 2011;72:553\u201362.","journal-title":"J Clinical Pharmacol."},{"key":"1134_CR13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2516.2011.02692.x","volume":"18","author":"S Guh","year":"2012","unstructured":"Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States 2008. Haemophilia. 2012;18:268\u201375.","journal-title":"Haemophilia."},{"issue":"11","key":"1134_CR14","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3111\/13696998.2014.953679","volume":"17","author":"EP Armstrong","year":"2014","unstructured":"Armstrong EP, Malone DC, Krishnan S, Wessler M. Costs and utilization of hemophilia A and B patients with and without inhibitors. J Med Econ. 2014;17(11):798\u2013802.","journal-title":"J Med Econ"},{"key":"1134_CR15","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.1111\/j.1365-2516.2009.02100.x","volume":"16","author":"M Minno Di","year":"2009","unstructured":"Di Minno M, Di Minno G, Di Capua M, Cerbone A, Coppola A. Cost of care of haemophilia with inhibitors. Haemophilia. 2009;16:e190\u2013201.","journal-title":"Haemophilia."},{"key":"1134_CR16","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/hae.12121","volume":"19","author":"A Farrugia","year":"2013","unstructured":"Farrugia A, Cassar J, Kimber M, Bansal M, Fischer K, Auserwald G, et al. Treatment for life for severe haemophilia A \u2013 A cost-utility model for prophylaxis vs. on-demand treatment. Haemophilia. 2013;19:e228\u201338.","journal-title":"Haemophilia"},{"key":"1134_CR17","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1111\/hae.12456","volume":"20","author":"F Abbonizio","year":"2014","unstructured":"Abbonizio F, Giampaolo A, Coppola A, Italian Association of Haemophilia Centre, Arcieri R, Hassan HJ. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia. 2014;20:e243\u201350.","journal-title":"Haemophilia"},{"key":"1134_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2516.2011.02677.x","volume":"18","author":"LA Valentino","year":"2012","unstructured":"Valentino LA, Pipe SW, Tarantino MD, Ye X, Luo P. Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia. 2012;18:332\u20138.","journal-title":"Haemophilia."},{"key":"1134_CR19","unstructured":"Associa\u00e7\u00e3o Portuguesa de Hemofilia. Available from: www.aphemofilia.pt . Accessed August 2015."},{"key":"1134_CR20","unstructured":"Minist\u00e9rio da Sa\u00fade. Grupo Trabalho criado pelo despacho n\u00b0 4319\/2013 de Sua Excel\u00eancia o Secret\u00e1rio de Estado Adjunto do Minist\u00e9rio da Sa\u00fade. Di\u00e1rio da R\u00e9publica n\u00b0 59, 2\u00aa S\u00e9rie, 25 de Mar\u00e7o de 2013."},{"key":"1134_CR21","unstructured":"Direc\u00e7\u00e3o-Geral de Sa\u00fade. Available from: www.dgs.pt . Accessed August 2015."},{"key":"1134_CR22","unstructured":"Infarmed. Autoridade Nacional do Medicamento e Produtos de Sa\u00fade I.P. Available from: www.infarmed.pt . Accessed August 2015"},{"key":"1134_CR23","unstructured":"Organization to Economic Co Operation and Development. Health at a Glance 2013, OECD Indicators. 2013. Available from: www.oecd.org\/els\/health-systems\/Health-at-a-Glance-2013.pdf . Accessed August 2015."},{"key":"1134_CR24","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the Management of Hemophilia. Haemophilia. 2013;19:e1\u201347.","journal-title":"Haemophilia."},{"issue":"Suppl 3","key":"1134_CR25","first-page":"s567","volume":"12","author":"Y Kodra","year":"2014","unstructured":"Kodra Y, Cavazza M, Schieppati A, Santis M, Armeni P, Arcieri R, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Tranfus. 2014;12 Suppl 3:s567\u201375.","journal-title":"Blood Tranfus"},{"key":"1134_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1750-1172-9-39","volume":"9","author":"S Henrad","year":"2014","unstructured":"Henrad S, Devleesschauwer B, Beutels P, Callens M, De Smet F, Hermans C, et al. The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease. Orphanet J Rare Dis. 2014;9:39.","journal-title":"Orphanet J Rare Dis."},{"key":"1134_CR27","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1365-2516.2011.02713.x","volume":"18","author":"S Guh","year":"2012","unstructured":"Guh S, Grosse SD, McAlister S, Kessler CM, Soucie JM. Health care expenditures for Medicaid-covered males with hemophilia in the United States, 2008. Haemophilia. 2012;18:276\u201383.","journal-title":"Haemophilia."},{"key":"1134_CR28","doi-asserted-by":"crossref","first-page":"790","DOI":"10.18553\/jmcp.2007.13.9.790","volume":"9","author":"T Tencer","year":"2007","unstructured":"Tencer T, Friedman HS, Li McLeod J, Jonhson K. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. J Manag Care Pharm. 2007;9:790\u20138.","journal-title":"J Manag Care Pharm."},{"key":"1134_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1365-2516.2012.02754.x","volume":"18","author":"A Farrugia","year":"2012","unstructured":"Farrugia A, O'Mahony B, Cassar J. Health technology assessment and haemophilia. Haemophilia. 2012;18:152\u20137.","journal-title":"Haemophilia."},{"key":"1134_CR30","unstructured":"Medicaid Health Plans of America, Center for Best Practices. Adressing the needs of members with hemophilia in medicaid managed care: issues and implications for health plans. Clinical Brief. 2013. Available from: www.mhpa.org\/_upload\/MHPA%20Hemophilia%20Issue%20Brief%20final%20082113.pdf . Accessed August 2015."},{"key":"1134_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/hae.12370","volume":"20","author":"N Duncan","year":"2014","unstructured":"Duncan N, Roberson C, Lail A, Donfield S, Shapiro A. A haemophilia disease management programme targeting cost and utilization of specialty pharmaceuticals. Haemophilia. 2014;20:519\u201326.","journal-title":"Haemophilia."},{"key":"1134_CR32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/asheducation.V2012.1.362.3798344","volume":"2012","author":"G Young","year":"2012","unstructured":"Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program. 2012;2012:362\u20138.","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"1134_CR33","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1111\/hae.12169","volume":"19","author":"CR Hay","year":"2013","unstructured":"Hay CR. Purchasing factor concentrates in the 21st century through competitive tendering. Haemophilia. 2013;19:660\u20137.","journal-title":"Haemophilia."},{"issue":"Suppl 3","key":"1134_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/j.1365-2516.2010.02257.x","volume":"16","author":"MA Escobar","year":"2010","unstructured":"Escobar MA. Health economics in haemophilia: a review from the clinicians perspective. Haemophilia. 2010;16 Suppl 3:29\u201334.","journal-title":"Haemophilia"},{"key":"1134_CR35","unstructured":"Direc\u00e7\u00e3o-Geral da Sa\u00fade. Sele\u00e7\u00e3o e Uso de Produtos Terap\u00eauticos para o Tratamento de Utentes com Coagulopatias Cong\u00e9nitas. Norma 011\/2014. Available from: www.dgs.pt\/directrizes-da-dgs\/normas-e-circulares-normativas\/norma-n-0112014-de-31072014-.aspx . Accessed August 2015."},{"key":"1134_CR36","unstructured":"EUHANET. Improving the care of European citizens with inherited bleeding disorders. Available from: www.euhanet.org . Accessed August 2015."},{"key":"1134_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1182\/asheducation-2011.1.413","volume":"2011","author":"KA Johnson","year":"2011","unstructured":"Johnson KA, Zhou ZY. Costs of care in Hemophilia and possible implications of health care reform. Hematology. 2011;2011:413\u20138.","journal-title":"Hematology."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-015-1134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12913-015-1134-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-015-1134-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T09:12:28Z","timestamp":1653383548000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-015-1134-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["1134"],"URL":"https:\/\/doi.org\/10.1186\/s12913-015-1134-3","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"article-number":"484"}}